Tailored systemic therapy for colorectal cancer liver metastases

Carolin Czauderna; Kim Luley; Nikolas von Bubnoff; Jens U. Marquardt

doi:10.3390/ijms222111780

Tailored systemic therapy for colorectal cancer liver metastases

Carolin Czauderna, Kim Luley, Nikolas von Bubnoff, Jens U. Marquardt^*

^*Corresponding author for this work

University of Kiel

16 Citations (Scopus)

Abstract

Liver metastases are the most common site of metastatic spread in colorectal cancer. Current treatment approaches involve effective systemic therapies in combination with surgical and/or interventional strategies. Multimodal strategies greatly improved clinical outcomes of patients with metastatic colorectal cancer over the last decades. Identification of predictive and prognostic biomarkers helped to comprehensively refine individual targeted treatment approaches and resulted in median overall survival rates of 30 months or longer. Current guidelines, thus, recommend treatment selection according to patients’ performance status, tumor localization and stage as well as the tumor’s molecular and genetic status. Here, we outline the latest developments in molecular decision-making for patients with upfront resectable, potentially or initially unresectable and non/never-resectable colorectal cancer liver metastases.

Original language	English
Article number	11780
Journal	International Journal of Molecular Sciences
Volume	22
Issue number	21
ISSN	1661-6596
DOIs	https://doi.org/10.3390/ijms222111780
Publication status	Published - 01.11.2021

Funding

Conflicts of Interest: J.U.M. reports receiving speaker’s honoraria from Roche AG and Bayer. N.v.B. reports receiving research funding from Novartis. K.L. reports receiving lecture fees from Sanofy gemzyme and congress support from Ipsen. C.C. reports receiving consulting fees from MSD and lecture fees from EISAI. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the manuscript.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3390/ijms222111780

Cite this

@article{42b2d485662e41d0a31c383f0a724902,

title = "Tailored systemic therapy for colorectal cancer liver metastases",

abstract = "Liver metastases are the most common site of metastatic spread in colorectal cancer. Current treatment approaches involve effective systemic therapies in combination with surgical and/or interventional strategies. Multimodal strategies greatly improved clinical outcomes of patients with metastatic colorectal cancer over the last decades. Identification of predictive and prognostic biomarkers helped to comprehensively refine individual targeted treatment approaches and resulted in median overall survival rates of 30 months or longer. Current guidelines, thus, recommend treatment selection according to patients{\textquoteright} performance status, tumor localization and stage as well as the tumor{\textquoteright}s molecular and genetic status. Here, we outline the latest developments in molecular decision-making for patients with upfront resectable, potentially or initially unresectable and non/never-resectable colorectal cancer liver metastases.",

author = "Carolin Czauderna and Kim Luley and \{von Bubnoff\}, Nikolas and Marquardt, \{Jens U.\}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors.",

year = "2021",

month = nov,

day = "1",

doi = "10.3390/ijms222111780",

language = "English",

volume = "22",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "21",

}

TY - JOUR

T1 - Tailored systemic therapy for colorectal cancer liver metastases

AU - Czauderna, Carolin

AU - Luley, Kim

AU - von Bubnoff, Nikolas

AU - Marquardt, Jens U.

PY - 2021/11/1

Y1 - 2021/11/1

N2 - Liver metastases are the most common site of metastatic spread in colorectal cancer. Current treatment approaches involve effective systemic therapies in combination with surgical and/or interventional strategies. Multimodal strategies greatly improved clinical outcomes of patients with metastatic colorectal cancer over the last decades. Identification of predictive and prognostic biomarkers helped to comprehensively refine individual targeted treatment approaches and resulted in median overall survival rates of 30 months or longer. Current guidelines, thus, recommend treatment selection according to patients’ performance status, tumor localization and stage as well as the tumor’s molecular and genetic status. Here, we outline the latest developments in molecular decision-making for patients with upfront resectable, potentially or initially unresectable and non/never-resectable colorectal cancer liver metastases.

AB - Liver metastases are the most common site of metastatic spread in colorectal cancer. Current treatment approaches involve effective systemic therapies in combination with surgical and/or interventional strategies. Multimodal strategies greatly improved clinical outcomes of patients with metastatic colorectal cancer over the last decades. Identification of predictive and prognostic biomarkers helped to comprehensively refine individual targeted treatment approaches and resulted in median overall survival rates of 30 months or longer. Current guidelines, thus, recommend treatment selection according to patients’ performance status, tumor localization and stage as well as the tumor’s molecular and genetic status. Here, we outline the latest developments in molecular decision-making for patients with upfront resectable, potentially or initially unresectable and non/never-resectable colorectal cancer liver metastases.

UR - https://www.scopus.com/pages/publications/85117921988

U2 - 10.3390/ijms222111780

DO - 10.3390/ijms222111780

M3 - Scientific review articles

C2 - 34769209

AN - SCOPUS:85117921988

SN - 1661-6596

VL - 22

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 21

M1 - 11780

ER -

Tailored systemic therapy for colorectal cancer liver metastases

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this